Start-Up Quarterly Statistics, Q2 2014
This article was originally published in Start Up
Start-ups raised $893.9 million in Q2 2014, a 25% drop from last quarter’s record-setting $1.18 billion. Metabolic disease was the most prevalent therapeutic category involved in alliances; seven acquisitions were signed, five in the biopharma sector.
You may also be interested in...
The money raised in Series A financings for biopharma, medtech, and diagnostics start-ups is down 8% from the same period last year, but the number of deals is down even more dramatically.
Roche gets an option to acquire program addressing drug-resistant gram-negative infections when it reaches IND-filing status. Spero is working on a novel target found originally in infected tobacco plants.
Two-year-old Insitro penned a potential $2.07bn collaboration with Bristol Myers Squibb focused on the discovery and development of therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The start-up will apply its ISH platform to create induced pluripotent stem cell-derived disease models. BMS also announced a definitive agreement to acquire MyoKardia for $13.1bn in cash. Financing reached $10.4bn in biopharma, $1.4bn in device, and $1.7bn in diagnostics.